Financial Performance - The company reported a total revenue of CNY 1.5 billion for the year 2022, representing a year-on-year increase of 10%[19]. - The net profit attributable to shareholders was CNY 300 million, which is a 15% increase compared to the previous year[19]. - The company's operating revenue for 2022 was ¥2,077,355,184.20, a decrease of 7.13% compared to ¥2,236,776,376.12 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥55,981,935.11, representing a 29.76% increase from ¥43,143,838.36 in 2021[25]. - The gross profit margin for the pharmaceutical manufacturing sector was 79.73%, while the pharmaceutical distribution sector had a gross profit margin of 12.07%[65]. - The company achieved operating revenue of 2.077 billion yuan, a decrease of 7.13% compared to the previous year[47]. - The company reported a total revenue for 2022 of ¥2,077,355,184.20, representing a decrease of 7.13% compared to ¥2,236,776,376.12 in 2021[63]. - The pharmaceutical manufacturing sector contributed ¥770,700,824.90, accounting for 37.10% of total revenue, down 12.76% from the previous year[63]. - The pharmaceutical distribution sector generated ¥1,306,654,359.30, making up 62.90% of total revenue, with a decrease of 3.45% year-on-year[63]. User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching a total of 1 million active users by the end of 2022[19]. - The company plans to launch three new products in 2023, focusing on innovative drug delivery systems[19]. - Market expansion efforts include entering two new provinces, aiming for a 25% increase in market share in those regions[19]. - User data showed a 15% increase in active users, reaching 2 million by the end of the reporting period[116]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[116]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[123]. Research and Development - The company has allocated CNY 200 million for research and development in new technologies for the upcoming fiscal year[19]. - The company has a dedicated R&D center with a complete organizational structure and approximately 10,000 square meters of pilot and pilot test bases[49]. - The R&D model includes both independent development and collaborative research, forming a rich pipeline of products under development[49]. - The total R&D investment for 2022 was ¥28,248,468.31, a decrease of 33.81% compared to ¥42,677,839.70 in 2021[77]. - The proportion of R&D investment to operating revenue was 1.36%, down from 1.91% in the previous year, reflecting a decrease of 0.55%[77]. - The R&D expenditure for new products and technologies increased by 20% year-on-year, indicating a strong commitment to innovation[123]. - The company introduced 49 new talents focused on R&D, quality, and production, enhancing its operational capabilities[59]. - The company plans to focus on three core areas: anti-infection, analgesics, and psychiatric drugs, aiming to enhance product offerings through both internal development and external collaborations[97]. Strategic Initiatives and Acquisitions - A strategic acquisition of a smaller biotech firm was completed, expected to enhance the company's product pipeline and capabilities[19]. - A strategic acquisition of a local pharmaceutical company is expected to enhance the company's product portfolio and distribution network[117]. - The company has established an industrial merger and acquisition fund with a total committed capital of CNY 500 million to CNY 700 million, with a 30% stake in the fund management company[182]. Operational Efficiency and Cost Management - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[116]. - The company actively adjusted its product structure and improved management efficiency to achieve a nearly 30% increase in net profit despite the revenue decline[53]. - The company is committed to optimizing its pharmaceutical business while focusing on the industrial sector, aiming for "value maximization" in its operations[52]. Corporate Governance and Compliance - The company has a board of directors consisting of 8 members, including 3 independent directors, complying with legal and regulatory requirements[109]. - The company emphasizes information disclosure, ensuring timely and accurate information is available to all shareholders through designated media[110]. - The company has established an effective internal control system in compliance with relevant laws and regulations, ensuring risk identification and management[140]. - The internal control self-evaluation report indicated that there were no significant defects in financial reporting or non-financial reporting during the reporting period[142]. - The company has committed to maintaining an independent financial structure, including separate bank accounts and financial decision-making processes[161]. Social Responsibility and Community Engagement - The company maintains a robust investor relations management system, including hosting annual performance briefings and participating in investor reception activities[148]. - The company actively fulfills its social responsibilities, ensuring the protection of shareholders, employees, and customers' rights while adhering to sustainable development principles[148]. - The company has engaged in charitable activities to support rural infrastructure and improve living conditions, demonstrating its commitment to social responsibility[151]. - The company has committed to enhancing environmental protection by investing in projects such as wastewater treatment facilities, ensuring compliance with national standards[149]. Challenges and Risks - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[4]. - The company faces ongoing challenges in cost control due to rising labor and raw material costs, alongside depreciation expenses[36]. - The company faces risks from industry policy changes, including drug approval and pricing pressures, and will enhance product quality and R&D speed to adapt[100]. - Rising raw material prices and drug price reductions pose risks, prompting the company to boost market promotion and explore mergers and acquisitions[101].

Financial Performance - The company's operating revenue for Q1 2023 was ¥498,709,845.17, representing a 3.46% increase compared to ¥482,036,482.63 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was ¥16,705,869.02, a significant increase of 40.71% from ¥11,872,378.05 in Q1 2022[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,960,415.93, reflecting a 40.74% increase year-on-year[5] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0280, up 40.70% from ¥0.0199 in Q1 2022[5] - Operating profit for Q1 2023 reached CNY 21,621,826.38, compared to CNY 14,565,050.34 in the previous year, indicating a growth of 48.3%[22] - The net profit for the first quarter of 2023 was CNY 16,693,448.90, representing an increase of 40.5% compared to CNY 11,871,474.86 in the same period last year[24] - The company reported a total profit of CNY 20,942,175.12, which is an increase from CNY 14,050,032.57 year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was -¥130,571,632.68, a drastic decline of 3,266.62% compared to -¥3,878,417.69 in the previous year[5] - The company's cash and cash equivalents decreased by 41.20% to ¥372,524,823.30, primarily due to reduced cash collections and loan repayments[9] - Cash and cash equivalents decreased to CNY 372,524,823.30 from CNY 633,520,126.20 at the beginning of the year, a decline of 41.1%[20] - Total assets at the end of Q1 2023 were ¥2,457,157,151.47, down 6.83% from ¥2,636,633,493.03 at the end of the previous year[5] - Total assets decreased to CNY 2,457,157,151.47 from CNY 2,637,335,665.00, a reduction of 6.8%[21] - The total cash flow from operating activities was negative CNY 130,571,632.68, a significant decline from negative CNY 3,878,417.69 in the prior year[25] - The cash flow from investing activities was negative CNY 10,790,722.65, compared to negative CNY 2,058,938.77 in the previous year, indicating increased investment outflows[26] - The cash flow from financing activities was negative CNY 142,010,858.86, a significant increase from negative CNY 9,133,912.37 in the prior year[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,837[11] - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 25.82% of the shares, totaling 153,859,360 shares, with 69,607,360 shares frozen[11] - Peking University Health Management Co., Ltd. holds 11.80% of the shares, totaling 70,328,949 shares[11] - The top ten shareholders include several domestic non-state-owned entities, indicating a diverse ownership structure[11] - As of the end of the reporting period, a total of 69,607,360 shares held by Southwest Synthetic Pharmaceutical Group have been judicially frozen, but this will not affect the company's control or daily operations[14] - The company has not reported any significant impact on corporate governance due to the frozen shares[14] Research and Development - Research and development expenses increased by 70.18% to ¥3,805,765.92, indicating a significant rise in investment in R&D activities[9] Regulatory Approvals and Partnerships - The company received approval from the National Medical Products Administration for the drug supplement application for injectable cefotaxime sodium, which passed the consistency evaluation of generic drug quality and efficacy[13] - The company obtained a drug registration certificate for citric acid tamsulosin tablets, confirming compliance with registration requirements[16] - The company is involved in a partnership to establish a private equity investment fund with a target capital contribution of no less than 500 million RMB and no more than 700 million RMB[15] - The company has completed the deregistration of a fund management company due to historical complexities and lack of actual investment activities[15] Liabilities and Retained Earnings - Total liabilities decreased to CNY 1,063,406,151.62 from CNY 1,260,278,114.05, reflecting a decline of 15.6%[21] - The company's retained earnings increased to CNY 547,916,110.01 from CNY 531,210,240.99, a growth of 3.2%[21]

Group 1: Company Overview and Business Model - North University Medical has established a comprehensive medical service industry chain, including hospital management, pharmaceutical manufacturing, distribution, equipment leasing, medical insurance, management consulting, and medical information technology [1] - The company plans to acquire 10,000 hospital beds within the next three years as part of its hospital acquisition strategy [1] Group 2: Medical Information Technology - North University Medical is the first provider of medical information system solutions in China, enhancing hospital operational efficiency and patient settlement processes [2] - The company aims to collaborate with affiliated hospitals initially and gradually expand to other tertiary hospitals [2] Group 3: Medical Big Data Initiatives - The company is preparing to establish a medical big data center, integrating data from various healthcare institutions for comprehensive analysis [2] - The planned "Beijing University Medical Health Big Data Center" will focus on data collection and analysis from regional health systems [2] Group 4: Investor and Analyst Q&A Highlights - The company is optimistic about the market potential for liver disease detection devices, despite their current low revenue contribution [2] - The acquisition criteria for hospitals include geographic location, expertise of affiliated medical institutions, and existing collaborations in major cities [3] Group 5: Future Directions and Strategic Planning - The oncology specialty is identified as a key future direction for the company, with plans to establish a model for ownership and management of oncology hospitals [3] - The company is exploring effective equity incentive mechanisms for its management team to align interests and drive performance [3]

证券代码：000788 证券简称：北大医药 北大医药股份有限公司投资者关系活动记录表 编号：2020001 | --- | --- | --- | |----------------|-----------------------------------------|------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | √ | 其他 （参加由重庆上市公司协会联合约调研平台举办的辖 | | | | 区上市公司与机构投资者线上交流会） | | | | 本次线上交流会由重庆上市公司协会联合约调研平台举办， | | | | 通过约调研平台和腾讯会议系统完成，参会人员名单由约调 | | | | 研平台提供，包括北京中教创联投资管理有限公司、上海海 | | 参与单位名称及 | | 欣集团股份有限公司、江苏高科技产业投资有限公司、江苏 | | 人员姓名 | | 瑞 ...

证券代码：000788 证券简称：北大医药 北大医药股份有限公司投资者关系活动记录表 编号：2019002 | --- | --- | --- | |----------------|--------------------------|-----------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | | □媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 海南旭日盛德资产管理有限公司:杜小东 | | 人员姓名 | 中信建投证券股份有限公司 | : 唐玺、杨鳗、王茜、李冬萍、秦 | | | | 皓郎、吴婷婷、陈松林、陈婷婷、黄越 | | | | 重庆渝开发股份有限公司：文伦海 个人投资者：孙梦婷、杨晏舒、谢理、石庆龙、谢饶海、龚 | | | 家茂、舒晓兰、董鑫 | | | 时 ...

证券代码：000788 证券简称：北大医药 北大医药股份有限公司投资者关系活动记录表 编号：2018001 | --- | --- | --- | |----------------|----------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 汇丰前海证券有限责任公司：赵智捷、樊嘉蕾 | | 人员姓名 | 香港上海汇丰银行有限公司：温馨 | | | | 博裕资本投资管理有限公司：陈云章 | | | | 高观投资有限公司：邱中伟 | | | 时间 | 2018 年 6 月 25 | 日下午 13:30 | | 地点 | 公司会议室 | | | 上市公司接 | 证券部工作人员：郑鑫、任雪娟 | | | 待人员姓 ...

证券代码：000788 证券简称：北大医药 北大医药股份有限公司投资者关系活动记录表 编号：2018003 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券股份有限公司：王寒、车朋 | | 人员姓名 | | | | 时间 | 2018 年 9 月 18 | 日上午 10:00 | | 地点 | 公司会议室 | | | 上市公司接 | 员：任雪娟 | 董事会秘书：袁宇飞，证券事务代表：郑鑫，证券部工作人 | | 待人员姓名 | | 公司接待人员向投资者介绍了公司基本情况及发展战 | | 投资者关系活动 | | 略，并对投资者关注的问题进行了 ...

证券代码：000788 证券简称：北大医药 编号：2018002 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中天国富证券有限公司：杨苍松 | | | 人员姓名 | 润银长江投资有限公司：郭锋超 | | | 时间 | 2018 年 9 月 17 | 日下午 14:00 | | 地点 | 公司会议室 | | | 上市公司接 | | 董事会秘书：袁宇飞，证券事务代表：郑鑫，证券部工作人 | | 待人员姓名 | 员：任雪娟 | | | 投资者关系活动 | | 公司接待人员向投资者介绍了公司经营情况、发展战略 | | 主要内容介绍 ...